1 Day
Source:
المشهد العربي
Nanexa shares jump 122% on Novo Nordisk deal
The stock of the Swedish company "Nanexa" rose by 122% after announcing a global licensing agreement worth €1.17 billion with Novo Nordisk to develop long-acting treatments for obesity, diabetes, and heart diseases. The deal includes exclusive rights to use the "Farmosil" technology in five development programs, aiming to reduce the frequency of injections for patients and enhance the efficiency of chronic treatments.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)